Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BiomX Inc. COmmon Stock (NY:PHGE)

0.5902 +0.1002 (+20.45%)
Streaming Delayed Price Updated: 3:21 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BiomX Inc. COmmon Stock

< Previous 1 2 3 4 5 Next >
Why Celyad Oncology Is Trading Higher By Over 31%; Here Are 29 Stocks Moving Premarket
Gainers MAIA Biotechnology, Inc. (NASDAQ: MAIA) rose 37.9% to $8.00 in pre-market trading after jumping 30% on Friday. The company agreed to initially offer 2.00 million shares to the public at a $5.00... 
Via Benzinga
This Communication Services Stock Jumped 149%; Here Are 90 Biggest Movers From Friday
Gainers Getty Images Holdings, Inc. (NYSE: GETY) shares climbed 149.1% to close at $26.15 on Friday following its merger with special-purpose acquisition company (SPAC) CC Neuberger Principal Holdings... 
Via Benzinga
Short Volatility Alert: BiomX Inc.
On Thursday, shares of BiomX Inc. (NYSE: PHGE) experienced volatile short activity. After the activity, the stock price went up +18.89% to $1.07. The overall sentiment for PHGE has been Bearish. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning! It's time for another dive into the biggest pre-market stock movers as we check out what's happening Thursday morning! 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Good morning, investors! We're starting off the day with a breakdown of the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
This Healthcare Stock is Down By More Than 50%: Here's 25 Stocks Moving Premarket
Gainers 
Via Benzinga
Why BiomX Shares Are Trading Higher Today?
Via Benzinga
BiomX Slashes Its Workforce By 50%, Atopic Dermatitis Program To Be Delayed
Via Benzinga
The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
BiomX Announces Voluntary Delisting from the Tel Aviv Stock Exchange
From BiomX Inc.
Via Business Wire
Why Is Ceragon Networks Surging By 19%? 41 Stocks Moving In Tuesday's Mid-Day Session
Gainers Agile Therapeutics, Inc. (NASDAQ: AGRX) jumped 88.9% to $2.3986. Agile Therapeutics shares climbed over 10% on Monday amid the Supreme Court overturning Roe V Wade. 
Via Benzinga
Earnings Scheduled For May 11, 2022
Companies Reporting Before The Bell • Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning! It's time for another dive into the biggest pre-market stock movers as we go over the news for Tuesday morning! 
Via InvestorPlace
Boehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome Biomarkers
From BiomX Inc.
Via Business Wire
BiomX Announces Dosing of the First Two Patients in Phase 1b/2a Study of BX004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis
From BiomX Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
During Friday's trading, 69 companies set new 52-week lows. 
Via Benzinga
The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
BiomX Announces Corporate Restructuring
From BiomX Inc.
Via Business Wire
BiomX Announces Publication in the Journal, Bioinformatics
From BiomX Inc.
Via Business Wire
BiomX Reports First Quarter 2022 Financial Results and Provides Business Update
From BiomX Inc.
Via Business Wire
BiomX to Host Key Opinion Leader Event on BX004 for Treatment of Pseudomonas Aeruginosa Infections in Cystic Fibrosis Patients
From BiomX Inc.
Via Business Wire
103 Biggest Movers From Yesterday
Gainers 
Via Benzinga
BiomX to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 11, 2022
From BiomX Inc.
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Good morning! Another day of trading lies ahead and we're starting it off with the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
BiomX Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
From BiomX Inc.
Via Business Wire
Earnings Scheduled For March 30, 2022
Companies Reporting Before The Bell • Orgenesis (NASDAQ:ORGS) is likely to report earnings for its fourth quarter. • RumbleON (NASDAQ:RMBL) is estimated to report earnings for its Fiscal Year 2021. 
Via Benzinga
BiomX to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on March 30, 2022
From BiomX Inc.
Via Business Wire
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets. 
Via Benzinga
BiomX Presenting at Three Upcoming Investor Conferences
From BiomX Inc.
Via Business Wire
BiomX Announces Therapeutics Development Award of up to $5 Million from the Cystic Fibrosis Foundation
From BiomX Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.